Close



Mar 21, 2024 04:01PM
Nov 7, 2023 04:01PM
Oct 16, 2023 07:00AM
Sep 12, 2023 07:00AM
Sep 12, 2023 07:00AM
Aug 29, 2023 07:00AM
Aug 8, 2023 04:01PM Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jun 2, 2023 04:01PM
Jun 1, 2023 07:29AM
May 12, 2023 07:00AM
Apr 25, 2023 07:59AM
Apr 25, 2023 07:59AM
Mar 29, 2023 04:08PM
Mar 29, 2023 04:06PM Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Feb 27, 2023 07:59AM
Feb 27, 2023 07:59AM
Feb 6, 2023 07:56AM
Jan 17, 2023 06:42PM
Nov 8, 2022 04:01PM
Sep 13, 2022 04:01PM
Sep 13, 2022 07:00AM Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study
Sep 12, 2022 05:44AM
Sep 10, 2022 08:00AM
Sep 8, 2022 07:00AM
Sep 6, 2022 07:00AM
Aug 29, 2022 07:00AM
Aug 9, 2022 07:00AM
Jul 5, 2022 07:02AM Lyra Therapeutics (LYRA) Appoints Richard Nieman as Chief Medical Officer
Jul 5, 2022 07:00AM
Jul 5, 2022 07:00AM
Jun 17, 2022 04:01PM
May 26, 2022 07:00AM
May 10, 2022 07:00AM
May 5, 2022 07:00AM
Apr 29, 2022 09:09AM Lyra Therapeutics (LYRA) Reports Positive Data from LANTERN Phase 2 Study of LYR-210
Apr 29, 2022 09:07AM
Apr 25, 2022 07:03AM
Apr 25, 2022 07:00AM
Apr 21, 2022 07:00AM
Apr 13, 2022 07:00AM
Mar 9, 2022 11:13AM
Mar 9, 2022 07:04AM Lyra Therapeutics (LYRA) Reports Q4; Provides Corporate Update
Mar 9, 2022 07:00AM
Mar 7, 2022 07:05AM
Mar 7, 2022 07:00AM
Feb 28, 2022 07:00AM
Feb 17, 2022 07:09AM
Feb 17, 2022 07:00AM
Jan 24, 2022 07:00AM Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
Nov 11, 2021 07:00AM

251,775 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All